Headlines such as “Spain becomes cannabis hub as criminals fill tourism void” (The Guardian 9 October 2020) serve to remind us of the endemic demand for marijuana, the resultant profits to be made and enforcement agencies’ inability to control Europe’s illegal trade run by drug mafias. By contrast, Canada, on 17 October 2018 and following the example of Uruguay, elected to legalise adult personal possession, sharing and cultivation of recreational cannabis.
For the first time, the NHS has agreed to fund a prescription for an unlicensed cannabis-based medicine product (CBMP) for a child. On 14 September 2020, the NHS announced its decision to fund the treatment of Billy Caldwell who is severely epileptic. This decision comes nearly two years after the law changed on 1 November 2018, allowing for CBMP’s to be prescribed by specialists for patients who cannot be helped by other available licensed drugs.
The medical cannabis market continues to grow in the United Kingdom (UK). However, the cannabis markets in other jurisdictions, and in particular Canada, are developing at a greater rate. We take a look at new developments in Canada against a comparison of the current industry in the UK.
There 113 identified cannabidiols aka CBD’s found in the cannabis plant. There is much debate around the efficacy of CBD oil that does not contain the active ingredient, tetrahydrocannabinol (THC). THC is known to be the principle psychoactive constituent of cannabis.
Last October, the EU Novel Foods Committee met to consider the evidence on certain hemp derived products, including Cannabidiol [CBD], to evaluate whether they had been widely used for human consumption within the EU prior to the 15th of May 1997, that being the date upon which the original “Novel Food” regulation, (EC) 258/97 came into force.